Abstract
Twenty-one patients were prospectively randomized into a blinded double-armed crossover study comparing α-interferon (α-IFN, 106 IU in a 3.5% aqueous methycellulose base) with and without 1% nonoxynol-9. Nine and twelve patients were randomized to arms with (+N) and without (-N) 1% nonoxynol-9, respectively. Patients applied the gel to affected areas every 8 hr and were evaluated biweekly. Including those crossed over, 14 patients were treated with -N. Six of fourteen (43%) achieved complete responses: biopsy proven with at least 1 year follow-up (CR). One patient achieved a partial response with at least a 50% reduction in the total surface area of all lesions present (PR). Similarly, 13 patients were treated with +N. Two patients in this group were found to have invasive cancer and one to have HIV and thus were eliminated from statistical analysis. Of the remaining 10 patients, 3 had CRs (30%), 5 had PRs (50%), and 2 failed to respond. There was no significant difference in reponses between the two groups. Overall, 14 of 18 (67%) patients demonstrated some response to α-IFN applied topically. These data support the conclusion that α-IFN is an active agent in the treatment of vulvar intraepithelial neoplasia III.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 34-38 |
| Number of pages | 5 |
| Journal | Gynecologic Oncology |
| Volume | 37 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1990 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Obstetrics and Gynecology
- Oncology
Cite this
Prospective randomized trial of topical α-interferon (α-interferon gels) for the treatment of vulvar intraepithelial neoplasia III. / Spirtos, Nick M.; Smith, Lloyd H; Teng, Nelson N H.
In: Gynecologic Oncology, Vol. 37, No. 1, 1990, p. 34-38.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prospective randomized trial of topical α-interferon (α-interferon gels) for the treatment of vulvar intraepithelial neoplasia III
AU - Spirtos, Nick M.
AU - Smith, Lloyd H
AU - Teng, Nelson N H
PY - 1990
Y1 - 1990
N2 - Twenty-one patients were prospectively randomized into a blinded double-armed crossover study comparing α-interferon (α-IFN, 106 IU in a 3.5% aqueous methycellulose base) with and without 1% nonoxynol-9. Nine and twelve patients were randomized to arms with (+N) and without (-N) 1% nonoxynol-9, respectively. Patients applied the gel to affected areas every 8 hr and were evaluated biweekly. Including those crossed over, 14 patients were treated with -N. Six of fourteen (43%) achieved complete responses: biopsy proven with at least 1 year follow-up (CR). One patient achieved a partial response with at least a 50% reduction in the total surface area of all lesions present (PR). Similarly, 13 patients were treated with +N. Two patients in this group were found to have invasive cancer and one to have HIV and thus were eliminated from statistical analysis. Of the remaining 10 patients, 3 had CRs (30%), 5 had PRs (50%), and 2 failed to respond. There was no significant difference in reponses between the two groups. Overall, 14 of 18 (67%) patients demonstrated some response to α-IFN applied topically. These data support the conclusion that α-IFN is an active agent in the treatment of vulvar intraepithelial neoplasia III.
AB - Twenty-one patients were prospectively randomized into a blinded double-armed crossover study comparing α-interferon (α-IFN, 106 IU in a 3.5% aqueous methycellulose base) with and without 1% nonoxynol-9. Nine and twelve patients were randomized to arms with (+N) and without (-N) 1% nonoxynol-9, respectively. Patients applied the gel to affected areas every 8 hr and were evaluated biweekly. Including those crossed over, 14 patients were treated with -N. Six of fourteen (43%) achieved complete responses: biopsy proven with at least 1 year follow-up (CR). One patient achieved a partial response with at least a 50% reduction in the total surface area of all lesions present (PR). Similarly, 13 patients were treated with +N. Two patients in this group were found to have invasive cancer and one to have HIV and thus were eliminated from statistical analysis. Of the remaining 10 patients, 3 had CRs (30%), 5 had PRs (50%), and 2 failed to respond. There was no significant difference in reponses between the two groups. Overall, 14 of 18 (67%) patients demonstrated some response to α-IFN applied topically. These data support the conclusion that α-IFN is an active agent in the treatment of vulvar intraepithelial neoplasia III.
UR - http://www.scopus.com/inward/record.url?scp=0025262422&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025262422&partnerID=8YFLogxK
U2 - 10.1016/0090-8258(90)90303-3
DO - 10.1016/0090-8258(90)90303-3
M3 - Article
C2 - 2182407
AN - SCOPUS:0025262422
VL - 37
SP - 34
EP - 38
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 1
ER -